The 25,000-crore Emami Group plans to make serious foray into homoeopathic medicines. The Group, which had acquired two sick homoeopathic pharmacy companies – M Bhattacharya & Co and King & Co (Homoeo Chemist) – in 2007 and 2011, respectively, has now tied up with a German company Hevert-Arzneimittel GmbH for a pan-India strategy.

RK Jatia, who looks after medicine-related business verticals of the Group, said having synergised the strength of the two heritage entities in the past few years, it is now aiming to manufacture homoeopathic medicines at its plant near here.

“We have upgraded the plant to Euro GMP (good manufacturing practices) for producing the key liquid ingredient – mother tincher for all medicines. Through the collaboration, we would upgrade it further to commence improved production by April 2015”, he explained at an event to announce the deals.

Hevert and Emami group has also signed licensing agreement for manufacturing some of the Hevert formulations here, Emami said.

Apart from the technical collaboration -- GMP consultancy, the German company has chosen M Bhattacharya & Co as the marketer of select Hevert branded over-the-counter medicines.

Mathias Hevert, MD of the German company, said that Emami Group would initially market six of its OTC products through imports. “We would not invest money in M Bhattacharya but in technology and manufacturing practices”, he added.

Jatia said merger of M Bhattacharya & Co and King & Co was on the cards and could be implemented next year.

The entities currently have 12 own retail outlets in city and some 400 retail distribution points elsewhere in the country.

Jatia, who is MD of Emami FrankRoss Ltd (EFL), an allopathic medicine chain of the Group, said that the Rs 240 crore entity was expected to break even in 2015-16. “We aim to take its revenue to Rs 500 crore in the next three years through expansion of stores, e-commerce and hospital sales,” he said.

Related Topics
comment COMMENT NOW